Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01880840 · ClinicalTrials.gov registry record · Phase 4
Safety of Astepro 0.15% Nasal Spray and Astepro 0.1% Nasal Spray in Children Ages >6 Months to <6 Years With AR
A Phase 4 study, sponsored by Meda Pharmaceuticals.
- Completed
- Registry status
- Phase 4
- Development phase
- 191
- Enrollment target
NCT01880840 is a Phase 4 study that has completed, run by Meda Pharmaceuticals. The registered enrollment target is 191 participants.
The verdict
NCT01880840, a Phase 4 study, has completed, sponsored by Meda Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 191 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the safety of 2 different doses of the investigational use of an allergy medication (Astepro Nasal Spray) in the treatment of allergic rhinitis (AR). This is an open-label study; that is, parent and child will know which group each is in.
Interventions
- DRUG 205.5 mcg of azelastine hydrochloride
- DRUG 137 mcg of azelastine hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 191 participants |
| Start Date | 2013-06 |
| Est. Completion | 2014-08 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01880840
The ClinicalTrials.gov registry entry for NCT01880840 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 191 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Meda Pharmaceuticals, which has 19 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which 205.5 mcg of azelastine hydrochloride is the first listed.
NCT01880840 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01880840 about?
NCT01880840 is a clinical study titled "Safety of Astepro 0.15% Nasal Spray and Astepro 0.1% Nasal Spray in Children Ages >6 Months to <6 Years With AR". The purpose of this study is to compare the safety of 2 different doses of the investigational use of an allergy medication (Astepro Nasal Spray) in the treatment of allergic rhinitis (AR). This is an open-label study; that is, parent and child will know which group each is in.
What is the current status of trial NCT01880840?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 191 participants. The study started on 2013-06. Estimated completion is 2014-08.
What interventions are being tested in trial NCT01880840?
The interventions under investigation include: 205.5 mcg of azelastine hydrochloride (DRUG), 137 mcg of azelastine hydrochloride (DRUG).
Who is sponsoring clinical trial NCT01880840?
This trial is sponsored by Meda Pharmaceuticals, which has 19 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.